Amgen to Invest Over $600 Million in New Science and Innovation Center at U.S. Headquarters Read more
Boehringer’s HERNEXEOS Approved in China as First Oral Targeted Therapy for HER2-Mutant Advanced NSCLC Read more
FDA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer’s Maintenance Therapy Read more